Adocia SA (FRA:A89)

Market Cap	47.98M -69.7%
Revenue (ttm)	2.98M -76.8%
Net Income	-15.90M
EPS	-0.83
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,600
Open	2.380
Previous Close	2.322
Day's Range	2.380 - 2.380
52-Week Range	2.026 - 9.610
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company’s proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 80
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A89

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error